|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver cancer incidence and mortality in China: Temporal trends and projections to 2030显示文摘Objective: Liver cancer is one of the most common cancers and major cause of cancer deaths in China,which accounts for over 50% of new cases and deaths worldwide.The systematic liver cancer statistics including of projection through 2030 could provide valuable information for prevention and control strategies in China,and experience for other countries.Methods: The burden of liver cancer in China in 2014 was estimated using 339 cancer registries' data selected from Chinese National Cancer Center(NCC).Incident cases of 22 cancer registries were applied for temporal trends from 2000 to 2014.The burden of liver cancer through 2030 was projected using age-period-cohort model.Results: About 364,800 new cases of liver cancer(268,900 males and 95,900 females) occurred in China,and about 318,800 liver cancer deaths(233,500 males and 85,300 females) in 2014.Western regions of China had the highest incidence and mortality rates.Incidence and mortality rates decreased by about 2.3% and 2.6% per year during the period of 2000-2014,respectively,and would decrease by more than 44% between 2014 and 2030 in China.The young generation,particularly for those aged under 40 years,showed a faster down trend.Conclusions: Based on the analysis,incidence and mortality rates of liver cancer are expected to decrease through 2030,but the burden of liver cancer is still serious in China,especially in rural and western areas.Most cases of liver cancer in China can be prevented through vaccination and more prevention efforts should be focused on high risk groups. | Rongshou Zheng Chunfeng Qu Siwei Zhang Hongmei Zeng Kexin Sun Xiuying Gu Changfa Xia Zhixun Yang He Li Wenqiang Wei Wanqing Chen Jie He | 2018 | Chinese Journal of Cancer Research2018，30，6： | 132 |
| 2 | No expenditure difference among patients with liver cancer at stageⅠ-ⅣV:Findings from a multicenter cross-sectional study in China显示文摘Objective:The number of liver cancer patients in China accounts for more than half of the world.However,China currently lacks national,multicenter economic burden data,and meanwhile,measuring the differences among different subgroups will be informative to formulate corresponding policies in liver cancer control.Thus,the aim of the study was to measure the economic burden of liver cancer by various subgroups.Methods:A hospital-based,multicenter and cross-sectional survey was conducted during 2012・2014,covering 39 hospitals and 21 project sites in 13 provinces across China.The questionnaire covers clinical information,sociology,expenditure,and related variables.All expenditure data were reported in Chinese Yuan(CNY)using 2014 values.Results:A total of 2,223 liver cancer patients were enrolled,of whom 59.61%were late-stage cases(III-IV),and 53.8%were hepatocellular carcinoma.The average total expenditure per liver cancer patient was estimated as 53,220 CNY,including 48,612 CNY of medical expenditures(91.3%)and 4,608 CNY of non-medical expenditures(8.7%).The average total expenditures in stage I,H,m and stage IV were 52,817 CNY,50,877 CNY,50,678 CNY and 54,089 CNY(P>0.05),respectively.Non-medical expenditures including additional meals,additional nutrition care,transportation,accommodation and hired informal nursing were 1,453 CNY,839 CNY,946 CNY,679 CNY and 200 CNY,respectively.The one-year out-of-pocket expenditure of a newly diagnosed patient was 24,953 CNY,and 77.2%of the patients suffered an unmanageable financial burden.Multivariate analysis showed that overall expenditure differed in almost all subgroups(P<0.05),except for sex,clinical stage,and pathologic type.Conclusions:There was no difference in treatment expenditure for liver cancer patients at different clinical stages,which suggests that maintaining efforts on treatment efficacy improvement is important but not enough.To fiirtherly reduce the overall economic burden from liver cancer,more effort should be given to primary and secondary prevention strategies. | Haike Lei Lin Lei Jufang Shi Yongzhong Wu Ling Liang Huiyao Huang Mei He Fangzhou Bai Maomao Cao Hui Qiu Yuting Wang Chengcheng Liu Jia Du Hong Wang Yan Zhang Mengdi Cao Ji Peng Ni Li Chunfeng Qu Min Dai Wanqing Chen Jie He | 2020 | Chinese Journal of Cancer Research2020，32，4： | 7 |
| 3 | Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease:a randomized, double-blind,parallel,placebo-controlled,fixed-dose study显示文摘Background:Rasagiline is a monoamine oxidase-B inhibitor used for Parkinson’s disease(PD)treatment,but its effectiveness on Chinese patients is unclear.This study aimed to evaluate the efficacy and safety of rasagiline monotherapy in Chinese patients with early PD.Methods:A 26-weeks,randomized,double-blind,placebo-controlled study has been performed at 15 sites in China and enrolled outpatients(≥35 years old)with idiopathic PD without a history of using any dopaminergic drugs.Participants were randomized 1:1 to receive rasagiline 1 mg once daily or placebo.The primary endpoint was the change of the Unified Parkinson’s Disease Rating Scale(UPDRS)total score from baseline to 26 weeks treatment.Secondary endpoints included changes in UPDRS subscale scores from part Ⅰ to Ⅲ.Health status was assessed with the PD Questionnaire(PDQ)-39 and EuroQol-Five-Dimension(EQ-5D)questionnaire.Safety profile was collected until 30 weeks after randomization.Results:A total of 130 patients(n=65/group)were recruited,and 127(rasagiline,n=64;placebo,n=63)were included in the full analysis set.Baseline characteristics were comparable between the two groups.The decrease in the mean UPDRS total score was greater in the rasagiline group than in the placebo group(−3.18±0.95 vs.−0.18±0.98,P=0.025),and the mean UPDRS part I non-motor symptoms score(−0.54±0.15 vs.-0.08±0.15,P=0.003)were significantly decreased in the rasagiline group compared with placebo treated patients.An improvement trend was observed in the active treatment group for the subscales evaluation with parts Ⅱ and Ⅲ,while the difference to placebo was not statistically significant.Life quality assessed by the EQ-5D visual analog scale improved in the rasagiline group but worsened in placebo treated patients.The overall incidence of treatment-emergent adverse events(AEs)was slightly lower in the rasagiline group(41.5%)than in the placebo group(46.2%).Conclusions:Rasagiline is effective,safe,and well tolerated as monotherapy for the treatment of Chinese PD patients. | Zhenxin Zhang Jian Wang Shengdi Chen Chunfeng Liu Baorong Zhang Rong Peng Shenggang Sun Xiangru Sun Gang Zhao Qiumin Qu Yansheng Li Suiqiang Zhu Xiaoping Pan Ming Shao Yanping Wang | 2018 | Translational Neurodegeneration2018，7，1： | 3 |
| 4 | A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBs Ag carriers显示文摘Objective: Hepatocellular carcinoma(HCC) development among hepatitis B surface antigen(HBs Ag) carriers shows gender disparity, influenced by underlying liver diseases that display variations in laboratory tests. We aimed to construct a risk-stratified HCC prediction model for HBs Ag-positive male adults.Methods: HBs Ag-positive males of 35-69 years old(N=6,153) were included from a multi-center populationbased liver cancer screening study. Randomly, three centers were set as training, the other three centers as validation. Within 2 years since initiation, we administrated at least two rounds of HCC screening using Bultrasonography and α-fetoprotein(AFP). We used logistic regression models to determine potential risk factors,built and examined the operating characteristics of a point-based algorithm for HCC risk prediction.Results: With 2 years of follow-up, 302 HCC cases were diagnosed. A male-ABCD algorithm was constructed including participant's age, blood levels of GGT(γ-glutamyl-transpeptidase), counts of platelets, white cells,concentration of DCP(des-γ-carboxy-prothrombin) and AFP, with scores ranging from 0 to 18.3. The area under receiver operating characteristic was 0.91(0.90-0.93), larger than existing models. At 1.5 points of risk score,26.10% of the participants in training cohort and 14.94% in validation cohort were recognized at low risk, with sensitivity of identifying HCC remained 100%. At 2.5 points, 46.51% of the participants in training cohort and 33.68% in validation cohort were recognized at low risk with 99.06% and 97.78% of sensitivity, respectively. At 4.5 points, only 20.86% of participants in training cohort and 23.73% in validation cohort were recognized at high risk,with positive prediction value of 22.85% and 12.35%, respectively.Conclusions: Male-ABCD algorithm identified individual's risk for HCC occurrence within short term for their HCC precision surveillance. | Yuting Wang Minjie Wang He Li Kun Chen Hongmei Zeng Xinyu Bi Zheng Zhu Yuchen Jiao Yong Wang Jian Zhu Hui Zhao Xiang Liu Chunyun Dai Chunsun Fan Can Zhao Deyin Guo Hong Zhao Jianguo Zhou Dongmei Wang Zhiyuan Wu Xinming Zhao Wei Cui Xuehong Zhang Jianqiang Cai Wanqing Chen Chunfeng Qu | 2021 | Chinese Journal of Cancer Research2021，33，3： | 3 |
| 5 | Novel cobalt base superalloy and its high-temperature flow behavior显示文摘包含钛和铝的新奇的钴底 superalloy 通过金属组织学,张力的测试,和高温度的等温的压缩变丑被调查。结果证明有罐头的钛和铝的合适的内容改进钴底 superalloy 的力量和韧性。Co3 (Ti,艾尔) 当新奇 superalloy 在 800 点是年老的时,有 L12 | TANG Chunfeng PAN Feng QU Xuanhui DUAN Baihua WANG Tianjian HE Xinbo | 2008 | Rare Metals2008，27，3： | 3 |
| 6 | Separation and Anti-Hantaan Virus Activity of Extracts from Alternanthera philoxcroides in vitro and in vivo显示文摘A water-soluble substance was extracted from the Chi-nese herb, Alternanthera philoxcroides with hot water and alcohol. Aliquots of this initial extract were further fractionated by treat-ment with ether, ethyl acetate and alcohol respectively. The four extracts were assayed for anti-viral activity against three serum, Hantaan virus 114 (HV114),HV435 and A9 strains. Results show that the four extracts are capable of inhibiting Hantaan virus propagation, of which extract No.1 has the best efficiency. The three dosage of extract No.1, which are used upon three Hantaan virus serum IC50, are 153, 157, 154 μ?/mL. New-born mice were made to be infected with HV114 and then fed in vivo with extract No.1 on the 3rd, 10th and 14th days after being infected by the virus. The treatment continued for 8 days with a dosage of 2.5 g/kg. Result shows that survival rates of mice were 75%, 50% and 0, respectively. The median time to death (MTDs) of the three groups were 37, 30, 23 days. | LIU Yingjuan YANG Zhanqiu DENG Haiying XIAO Hong QU Chunfeng | 2007 | Wuhan University Journal of Natural Sciences2007，12，6： | 2 |
| 7 | Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China显示文摘 | Zongtang Sun Taoyang Chen Snorri S. Thorgeirsson Qimin Zhan Jianguo Chen Ju-Hyun Park Peixin Lu Chu Chieh Hsia Nengjin Wang Libin Xu Lingling Lu Fei Huang Yuanrong Zhu Jianhua Lu Zhengping Ni Qinan Zhang Yuying Wu Guoting Liu Zhiyuan Wu Chunfeng Qu Mitche | 2013 | Carcinogenesis2013，，8： | 1 |
| 8 | AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma显示文摘Aflatoxin exposure is a crucial factor in promoting the development of primary hepatocellular carcinoma(HCC)in individuals infected with the hepatitis virus.However,the molecular pathways leading to its bioactivation and subsequent toxicity in hepatocytes have not been well-defined.Here,we carried out a genome-wide CRISPR-Cas9 genetic screen to identify aflatoxin B1(AFB1)targets.Among the most significant hits was the aryl hydrocarbon receptor(AHR),a ligand-binding transcription factor regulating cell metabolism,differentiation,and immunity. | Qing Zhu Yarui Ma Junbo Liang Zhewen Wei Mo Li Ying Zhang Mei Liu Huan He Chunfeng Qu Jianqiang Cai Xiaobing Wang Yixin Zeng Yuchen Jiao | 2021 | Signal Transduction and Targeted Therapy2021，6，9： | 1 |
| 9 | Antifungal dibenzofuran bis(bibenzyl)s from the liverwort Asterella angusta显示文摘 | Jianbo Qu Chunfeng Xie Huaifang Guo Wentao Yu Hongxiang Lou | 2007 | Phytochemistry2007，，13： | 1 |
| 10 | Correction: AHR mediates the Aflatoxin B1 toxicity associated with hepatocellular carcinoma显示文摘Correction to:Signal Transduction and Targeted Therapy http://gffzzd3cc09b8251d45dfsukbpbu5coo6v6opo.ffgz.tsg.suse.edu.cn/10.1038/s41392-021-00713-1 z published online 9 August 2021 After online publication of the article^(1),the authors noticed one inadvertent mistake occurred during the production process in Fig.7 that needs to be corrected.The correct data are provided as follows.The key findings of the article are not affected by these corrections.The original article has been corrected. | Qing Zhu Yarui Ma Junbo Liang Zhewen Wei Mo Li Ying Zhang Mei Liu Huan He Chunfeng Qu Jianqiang Cai Xiaobing Wang Yixin Zeng Yuchen Jiao | 2022 | Signal Transduction and Targeted Therapy2022，7，1： | 0 |
| 11 | Conventional type 1 dendritic cells in protective antitumor immunity and its potential in hepatocellular carcinoma显示文摘Immunotherapy is revolutionizing the clinical management of cancer patients by modulating T cells and natural killer cells.Dendritic cells(DCs)have the capacity to orchestrate the expansion and function of these effector cells both in lymphoid and non-lymphoid tissues of cancer patients.Distinct subtypes of DCs have various capacities to prime and activate different T cell responses.Here,we review conventional type 1 dendritic cells(cDC1s)and their crucial role in protective anti-tumor immunity.Targeting cDC1s as a cancer vaccine against the development of hepatocellular carcinoma will be discussed. | Chunfeng Qu Kun Chen Shao-Yan Cheng | 2020 | Hepatoma Research2020，6，7： | 0 |
| 12 | Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations:a randomized,double-blind study in China显示文摘Background:The use of adjunct rasagiline in levodopa-treated patients with Parkinson’s disease and motor fluctuations is supported by findings from large-scale clinical studies.This study is to investigate the efficacy and safety of adjunct rasagiline in Chinese patients with Parkinson’s disease,as a product registration study.Methods:This 16-week,randomized,double-blind,parallel-group,multicenter,placebo-controlled study of rasagiline 1 mg/day included levodopa-treated patients with Parkinson’s disease and motor fluctuations.The primary efficacy endpoint was mean change from baseline in total daily OFF time over 16 weeks.Secondary endpoints were Clinical Global Impressions–Improvement(CGI-I),and change in Unified Parkinson’s Disease Rating Scale(UPDRS)Activities of daily living(ADL)and Motor scores.Patient well-being(EQ-5D),and the frequency of adverse events were also assessed.Results:In total,324 levodopa-treated patients were randomized to rasagiline 1 mg/day(n=165)or placebo(n=159).Over 16 weeks,rasagiline statistically significantly reduced the mean[95% confidence interval]total daily OFF time versus placebo(−0.5 h[−0.92,−0.07];p=0.023).There were also statistically significant improvements versus placebo in CGI-I(−0.4 points[−0.61,−0.22];p<0.001),UPDRS-ADL OFF(−1.0 points[−1.75,−0.27];p=0.008),and UPDRS-Motor ON(−1.6 points[−3.05,−0.14];p=0.032)scores,as well as the EQ-5D utility index(p<0.05).Rasagiline was safe and well tolerated.Conclusions:In levodopa-treated Chinese patients with Parkinson’s disease and motor fluctuations,adjunct rasagiline 1 mg/day statistically significantly reduced OFF time,and improved daily function and overall well-being,versus placebo.Consistent with findings in other countries,adjunct rasagiline was proven efficacious and well tolerated in Chinese patients. | Zhenxin Zhang Ming Shao Shengdi Chen Chunfeng Liu Rong Peng Yansheng Li Jian Wang Suiqiang Zhu Qiumin Qu Xiaoying Zhang Haibo Chen Xiangru Sun Yanping Wang Shenggang Sun Baorong Zhang Jimei Li Xiaoping Pan Gang Zhao | 2018 | Translational Neurodegeneration2018，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员